Antiasthma medication and steroids redeemed within the 365-day observation period in the asthma subpopulation of the study population
| PCOS1 group | PCOS2 group | p-value# | Control group | p-value¶ | |
| Subjects | 266 | 3154 | 786 | ||
| SABA | 231 (88.2) | 2759 (88.9) | 0.7125 | 670 (86.56) | 0.5048 |
| ICS | 147 (56.1) | 1468 (47.3) | 0.0062 | 385 (49.7) | 0.0748 |
| ICS/LABA | 17 (6.5) | 282 (9.1) | 0.1556 | 57 (7.4) | 0.6342 |
| LAMA/LABA | 0 (0) | 13 (0.4) | 0.2938 | 5 (0.7) | 0.1922 |
| LABA | 12 (4.6) | 171 (5.5) | 0.5235 | 54 (7.0) | 0.1698 |
| LAMA | 0 (0) | 4 (0.1) | 0.5609 | 1 (0.1) | 0.5605 |
| Biological treatment+ | 0 (0) | 0 (0) | 0 (0) | ||
| Oral steroid | 6 (2.3) | 120 (3.9) | 0.1966 | 31 (4.0) | 0.1960 |
| Local steroid | 1 (0.40) | 4 (0.1) | 0.3077 | 0 (0) | 0.0855 |
| Nasal steroid | 32 (12.2) | 347 (11.2) | 0.6122 | 108 (14.0) | 0.4765 |
Data are presented as n or n (%), unless otherwise stated. PCOS: polycystic ovary syndrome; SABA: short-acting β2-agonist; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist. #: difference between PCOS1 and PCOS2; ¶: difference between PCOS1 and control; +: reslizumab, mepolizumab, omalizumab. p≤0.05 statistically significant.